AstraZeneca Shares Fall After Breast Cancer Drug Fails Late-Stage Trial

AstraZeneca PLC (NASDAQ:AZN) announced on Friday that its breast cancer treatment, Etcamah, failed to meet the primary endpoint in a late-stage clinical trial, a setback that prompted a drop in its share price. The company's U.S.-listed shares fell 3% in aftermarket trading following the news.

Trial Fails to Show Significant Benefit

The study evaluated Etcamah in combination with palbociclib, another cancer therapy, for patients with a specific form of advanced breast cancer who had not previously received treatment. The primary goal was to demonstrate a statistically significant improvement in progression-free survival (PFS), meaning the length of time patients live with the disease without it worsening.

According to AstraZeneca, the drug combination showed only a "numerical improvement" in this patient group and did not meet the trial's main objective. The company stated that the full data from the trial will be presented at a future date.

Ad

Context for Investors

This outcome is notable as it follows recent positive regulatory news for the drug. Last week, the U.S. Food and Drug Administration (FDA) granted Etcamah an accelerated approval for use alongside a class of targeted cancer medicines known as CDK4/6 inhibitors.

While accelerated approvals allow earlier patient access to promising drugs, they are often conditional on subsequent trials confirming the clinical benefit. The failure of this late-stage trial to meet its primary endpoint could raise questions for investors and regulators about the drug's future prospects and path to full approval.